Project Name: Collaborative Working relating to improved lipid management in England associated with the implementation of Leqvio® (inclisiran) into the lipid management pathway.
Project Summary:
The principal aim of the Programme is to develop and/or improve patient pathways to support improved lipid management, which is one of the priorities set out in the NHS Long Term Plan, including activities associated
with the implementation of Inclisiran in England.
Planned Milestones:
The activities and milestones of the Collaboration Project form a multi-year programme where activities are defined for each year of activity throughout the Term from 29th July 2021 to the 31st August 2024.
Due to the evolving nature of the specific activities required to achieve the anticipated outcomes, the Parties have agreed to update the Agreement on a yearly basis and captured in the Master Agreement.
Expected Benefits:
The Collaborative Project is intended to deliver the following expected benefits to:
1. patients, patient population of the following patient user groups
- Faster access to innovative and cost effective medicines for patients as part of a diagnosis and treatment pathway
- Care closer to home
- More equitable access to care
- Better information on conditions and treatment options
- Improved patient outcomes
2. the NHS
- Highlights England as a prime destination to implement innovative medicines faster and more cost-effectively
- More patients treated appropriately in primary care
- Better use of finite secondary care resources
- Supports one of the key priorities set out in the Long Term Plan regarding cardiovascular disease
3. Novartis
- Primary care treatment pathway in place to support population health approach to Inclisiran
- Improved reputation across the NHS in England
- Better understanding of NHSE&I and the primary care network
Start Date & Duration: 29th July 2021 – 31st August 2024
UK2310178813